From Clinical Management to Catheter Ablation Indication

Raffaella Mistrulli,Armando Ferrera,Melwyn Luis Muthukkattil,Allegra Battistoni,Giovanna Gallo,Emanuele Barbato,Francesco Raffaele Spera,Damiano Magrì
DOI: https://doi.org/10.3390/jcm13020501
IF: 3.9
2024-01-17
Journal of Clinical Medicine
Abstract:Atrial fibrillation (AF) is the most common arrhythmia in patients affected by cardiomyopathies. Reports estimate a prevalence of 27% in patients with hypertrophic cardiomyopathy (HCM) and 40% in patients with cardiac amyloidosis (CA). The presence of AF typically results in progressive functional decline, an increased frequency of hospitalizations for heart failure, and a higher thromboembolic risk. Medical management using mainly beta-blockers or amiodarone has produced variable outcomes and a high rate of recurrence. Catheter ablation reduces symptom burden and complications despite a moderate rate of recurrence. Recent evidence suggests that an early rhythm control strategy may lead to more favorable short- and long-term outcomes. In this review, we summarize contemporary data on the management of AF in patients with cardiomyopathy (HCM and CA) with particular reference to the timing and outcomes of ablation procedures.
medicine, general & internal
What problem does this paper attempt to address?